54 related articles for article (PubMed ID: 38482433)
1. Immune checkpoint inhibitors
Liu S; Dou L; Li S
Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
[TBL] [Abstract][Full Text] [Related]
2. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC).
Liu SY; Wu YL
Expert Opin Investig Drugs; 2020 Dec; 29(12):1355-1364. PubMed ID: 33044117
[TBL] [Abstract][Full Text] [Related]
3. A real-world evaluation of tislelizumab in patients with head and neck cancer.
Zheng B; Huang Z; Liu W; Zhao D; Xu X; Xiao S; Sun Y; Wang W
Transl Cancer Res; 2024 Feb; 13(2):808-818. PubMed ID: 38482433
[TBL] [Abstract][Full Text] [Related]
4. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
6. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
[TBL] [Abstract][Full Text] [Related]
7. Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study.
Wang Z; Bi H; Wang YD; Liu Q; Shao B; Li CQ; Fu C; Fu S; Shan GY; Chen A; Lv CC; Zeng Y
Actas Urol Esp (Engl Ed); 2024 May; 48(4):295-303. PubMed ID: 38160794
[TBL] [Abstract][Full Text] [Related]
8. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
[TBL] [Abstract][Full Text] [Related]
9. PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study.
Fang Q; Xu P; Cao F; Wu D; Liu X
Cancer Immunol Immunother; 2023 Dec; 72(12):4161-4168. PubMed ID: 37804437
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant PD-1/PD-L1 inhibitors combined with chemotherapy had a higher ORR than mono-immunotherapy in untreated HNSCC: Meta-analysis.
Chen S; Yang Y; Wang R; Fang J
Oral Oncol; 2023 Oct; 145():106479. PubMed ID: 37478574
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
Miao J; Wang L; Tan SH; Li JG; Yi J; Ong EHW; Tan LLY; Zhang Y; Gong X; Chen Q; Xiang YQ; Chen MY; Guo Y; Lv X; Xia WX; Tang L; Deng X; Guo X; Han F; Mai HQ; Chua MLK; Zhao C
JAMA Oncol; 2022 Oct; 8(12):1776-85. PubMed ID: 36227615
[TBL] [Abstract][Full Text] [Related]
12. Current status and advances of immunotherapy in nasopharyngeal carcinoma.
Xu JY; Wei XL; Wang YQ; Wang FH
Ther Adv Med Oncol; 2022; 14():17588359221096214. PubMed ID: 35547095
[TBL] [Abstract][Full Text] [Related]
13. Head and neck cancer: Current challenges and future perspectives.
Bhat GR; Hyole RG; Li J
Adv Cancer Res; 2021; 152():67-102. PubMed ID: 34353444
[TBL] [Abstract][Full Text] [Related]
14. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi YR; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Liu Z; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Feng H; Yao S; Keegan P; Xu RH
Nat Med; 2021 Sep; 27(9):1536-1543. PubMed ID: 34341578
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
